BCR-ABL1 transcript at 3months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib

British Journal of Haematology

Volumn 160, Issue 5, 2013, Pages 630-639

  Kim, Dennis D ^a   Lee, Honggi ^a   Kamel Reid, Suzanne ^b   Lipton, Jeffrey H ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

BCR ABL1 transcript level; Chronic myeloid leukaemia; Second generation tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB;

ADULT; AGED; ARTICLE; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LONG TERM CARE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RNA, MESSENGER; RNA, NEOPLASM; THIAZOLES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84874000814     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12187     Document Type: Article

References (14)

1. Branford, S., Fletcher, L., Cross, N.C., Muller, M.C., Hochhaus, A., Kim, D.W., Radich, J.P., Saglio, G., Pane, F., Kamel-Reid, S., Wang, Y.L., Press, R.D., Lynch, K., Rudzki, Z., Goldman, J.M. & Hughes, T. (2008) Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood, 112, 3330-3338.
2. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L. & Larson, R.A. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355, 2408-2417.
3. Hanfstein, B., Muller, M.C., Hehlmann, R., Erben, P., Lauseker, M., Fabarius, A., Schnittger, S., Haferlach, C., Gohring, G., Proetel, U., Kolb, H.J., Krause, S.W., Hofmann, W.K., Schubert, J., Einsele, H., Dengler, J., Hanel, M., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C.F., Branford, S., Hughes, T.P., Spiekermann, K., Baerlocher, G.M., Pfirrmann, M., Hasford, J., Saussele, S. & Hochhaus, A. (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 26, 2096-2102.
4. Hochhaus, A., Saglio, G., Chuah, C., Pavlovsky, C., Garelick, M.B.B., Lambert, A. & Shah, N. (2011) Dasatinib and Imatinib-induced reductions in BCR-ABL transcript levels below 10% at 3months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of molecular response kinetics in the DASISION trial. Blood, 118, 2767.
5. Hughes, T.P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M.L., Gathmann, I., Bolton, A.E., van Hoomissen, I.C., Goldman, J.M. & Radich, J.P. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 349, 1423-1432.
6. Jabbour, E., Kantarjian, H., O'Brien, S., Shan, J., Garcia-Manero, G., Wierda, W., Ravandi, F., Borthakur, G., Rios, M.B. & Cortes, J. (2011) Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood, 117, 1822-1827.
7. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., Druker, B., Goldman, J., O'Brien, S.G., Russell, N., Fischer, T., Ottmann, O., Cony-Makhoul, P., Facon, T., Stone, R., Miller, C., Tallman, M., Brown, R., Schuster, M., Loughran, T., Gratwohl, A., Mandelli, F., Saglio, G., Lazzarino, M., Russo, D., Baccarani, M. & Morra, E. (2002a) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New England Journal of Medicine, 346, 645-652.
8. Kantarjian, H.M., O'Brien, S., Cortes, J.E., Smith, T.L., Rios, M.B., Shan, J., Yang, Y., Giles, F.J., Thomas, D.A., Faderl, S., Garcia-Manero, G., Jeha, S., Wierda, W., Issa, J.P., Kornblau, S.M., Keating, M., Resta, D., Capdeville, R. & Talpaz, M. (2002b) Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clinical Cancer Research, 8, 2167-2176.
9. Marin, D., Ibrahim, A.R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R.M., Clark, R.E., Apperley, J.F., Milojkovic, D., Bua, M., Pavlu, J., Paliompeis, C., Reid, A., Rezvani, K., Goldman, J.M. & Foroni, L. (2012) Assessment of BCR-ABL1 transcript levels at 3months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Journal of Clinical Oncology, 30, 232-238.
10. Merx, K., Muller, M.C., Kreil, S., Lahaye, T., Paschka, P., Schoch, C., Weisser, A., Kuhn, C., Berger, U., Gschaidmeier, H., Hehlmann, R. & Hochhaus, A. (2002) Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia, 16, 1579-1583.
11. Milojkovic, D., Nicholson, E., Apperley, J.F., Holyoake, T.L., Shepherd, P., Drummond, M.W., Szydlo, R., Bua, M., Foroni, L., Reid, A., Khorashad, J.S., de Lavallade, H., Rezvani, K., Paliompeis, C., Goldman, J.M. & Marin, D. (2010) Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica, 95, 224-231.
12. O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J.J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J.L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J.M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A.E., Capdeville, R. & Druker, B.J. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 348, 994-1004.
13. Press, R.D., Love, Z., Tronnes, A.A., Yang, R., Tran, T., Mongoue-Tchokote, S., Mori, M., Mauro, M.J., Deininger, M.W. & Druker, B.J. (2006) BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood, 107, 4250-4256.
14. Wang, L., Pearson, K., Ferguson, J.E. & Clark, R.E. (2003) The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. British Journal of Haematology, 120, 990-999.